---
title: "ONC.US (ONC.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ONC.US/news.md"
symbol: "ONC.US"
name: "ONC.US"
parent: "https://longbridge.com/en/quote/ONC.US.md"
datetime: "2026-05-20T08:14:29.850Z"
locales:
  - [en](https://longbridge.com/en/quote/ONC.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONC.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONC.US/news.md)
---

# ONC.US (ONC.US) — Related News

### [Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today](https://longbridge.com/en/news/286947117.md)
*2026-05-19T16:45:40.000Z*
> BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market 

### [<![CDATA[Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra]]>](https://longbridge.com/en/news/286601439.md)
*2026-05-15T18:15:33.000Z*
> The FDA has approved AstraZeneca's Fasenra for treating hypereosinophilic syndrome in patients aged 12 and older, based 

### [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi]]>](https://longbridge.com/en/news/286458336.md)
*2026-05-14T18:50:13.000Z*
> The FDA has granted accelerated approval to BeOne Medicines' Beqalzi, the first BCL2 inhibitor for relapsed mantle cell 

### [BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer](https://longbridge.com/en/news/286453582.md)
*2026-05-14T18:15:51.000Z*
> The FDA has granted accelerated approval to BeOne Medicines' BEQALZI (sonrotoclax) for adults with relapsed mantle cell 

### [Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)](https://longbridge.com/en/news/286337391.md)
*2026-05-14T01:05:20.000Z*
> Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK

### [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)
*2026-05-13T23:37:16.000Z*
> BeOne Medicines Ltd has received accelerated U.S. FDA approval for BEQALZI (sonrotoclax), the first BCL2 inhibitor for a

### [BeOne's Venclexta challenger Beqalzi nets FDA approval](https://longbridge.com/en/news/286315985.md)
*2026-05-13T20:50:25.000Z*
> BeOne Medicines has received FDA approval for Beqalzi (sonrotoclax), the first BCL-2 inhibitor specifically approved for